Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Grifols_S._A.
|
| gptkbp:awards |
various industry awards
|
| gptkbp:ceo |
gptkb:David_Johnson
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:collaborations |
academic institutions
healthcare providers research institutions biopharmaceutical companies industry consortia |
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:founder |
gptkb:David_Johnson
|
| gptkbp:goal |
develop novel therapies
enhance drug discovery accelerate clinical development |
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Giga Gen
|
| gptkbp:impact |
patient care
biotechnology advancements healthcare innovation |
| gptkbp:industry |
gptkb:Company
|
| gptkbp:invention |
multiple
|
| gptkbp:investment |
gptkb:Company
|
| gptkbp:mission |
improve patient outcomes
|
| gptkbp:partnership |
government agencies
non-profit organizations various pharmaceutical companies clinical research organizations |
| gptkbp:products |
Giga Gen's antibody platform
Giga Gen's therapeutic antibodies Giga Gen's vaccine candidates Giga M Ab Giga M Ab platform |
| gptkbp:receives_funding_from |
gptkb:Series_A
gptkb:Series_B Series C |
| gptkbp:research |
immune response
|
| gptkbp:research_areas |
monoclonal antibodies
vaccine development therapeutic antibodies |
| gptkbp:services |
therapeutic development
antibody engineering |
| gptkbp:targets |
gptkb:healthcare_organization
autoimmune diseases infectious diseases |
| gptkbp:technology |
gptkb:software_framework
bioinformatics next-generation sequencing genomic analysis antibody discovery protein engineering |
| gptkbp:vision |
transforming medicine
|
| gptkbp:website |
www.gigagen.com
|